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Abstract
Background In this study, we sought to determine the
effect of the mean transprosthetic pressure gradient (TPG),
measured at 6 weeks after aortic valve replacement (AVR)
or AVR with coronary artery bypass grafting (CABG) on
late all-cause mortality.
Methods Between January 1998 and March 2012, 2,276
patients (mean age 68 ± 11 years) underwent TPG ana-
lysis at 6 weeks after AVR (n = 1,318) or AVR with
CABG (n = 958) at a single institution. Mean TPG was
11.6 ± 7.8 mmHg and median TPG 11 mmHg. Based on
the TPG, the patients were split into three groups: patients
with a low TPG (\10 mmHg), patients with a medium
TPG (10–19 mmHg) and patients with a high TPG
(C20 mmHg). Cox proportional-hazard regression analysis
was used to determine univariate predictors and multivar-
iate independent predictors of late mortality.
Results Overall survival for the entire group at 1, 3, 5,
and 10 years was 97, 93, 87 and 67 %, respectively. There
was no significant difference in long-term survival between
patients with a low, medium or high TPG (p = 0.258).
Independent predictors of late mortality included age,
diabetes, peripheral vascular disease, renal dysfunction,
chronic obstructive pulmonary disease, a history of a
cerebrovascular accident and cardiopulmonary bypass
time. Prosthesis–patient mismatch (PPM), severe PPM and
TPG measured at 6 weeks postoperatively were not sig-
nificantly associated with late mortality.
Conclusions TPG measured at 6 weeks after AVR or
AVR with CABG is not an independent predictor of all-
cause late mortality and there is no significant difference in
long-term survival between patients with a low, medium or
high TPG.
Keywords Prosthesis  Mismatch  Aortic valve 
Replacement  Gradient  Survival analysis
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Implantation of a prosthetic aortic valve too small for the
patient’s body size could lead to an increased hemodynamic
burden by creating left ventricular outflow obstruction,
resulting in a higher mean transprosthetic pressure gradient
(TPG). This condition after aortic valve replacement (AVR)
is known as prosthesis–patient mismatch (PPM) and occurs
when the effective orifice area (EOA) of the implanted
valve prosthesis is too small in relation to the body surface
area (BSA) of the patient [1, 2]. PPM is expressed by the
indexed EOA (EOAI). The EOAI is calculated by dividing
the corresponding EOA of each valve type and size by each
patient’s BSA. Although different cut-off values exist to
define PPM, usually a cut-off value of EOAI B0.85 cm2/m2
is chosen, as described by Pibarot and colleagues [1]. An
EOAI \0.65 cm2/m2 is regarded as severe PPM [1, 3, 4].
The EOAI has been shown to negatively correlate with the
TPG [5–7] and other studies have shown that despite normal
prosthesis function, relatively high TPG can be measured
after AVR [3, 4, 8–12].
Studies examining the impact of an undersized pros-
thetic aortic valve on long-term survival mainly focus on
describing the existence of PPM. The impact of PPM on
mortality after AVR is still a controversial topic. Several
studies have shown that PPM is associated with increased
short-term and/or long-term mortality after AVR [13–16].
Other studies contradict these findings and report that PPM
does not have a significant impact on survival [17–24].
In this study we focussed on the main hemodynamic
consequence of PPM, and we sought to determine the
effect of a higher TPG, measured at 6 weeks after AVR or
AVR with coronary artery bypass grafting (AVR with
CABG), on late all-cause mortality.
Methods
Study design
This is a retrospective, observational study on consecutive
patients. Data were obtained from the Institutional data-
base, normally utilized for patient care. Clinical data,
echocardiographic data, catheterization data, and surgical
reports were entered into the institutional database pro-
spectively and analyzed retrospectively. Because anony-
mous standard clinical follow-up check-ups were used to
collect and analyze data, the study was approved by the
Medical Ethical Committee.
Patients
Between January 1998 and March 2012, 2,957 patients
underwent AVR (n = 1,701) or AVR with CABG
(n = 1,256) using a mechanical or stented biological aortic
valve prosthesis at our institution. Only patients who
underwent transthoracic echocardiography (TTE) at
6 weeks after AVR or AVR with CABG were analyzed,
leading to the exclusion of 681 patients, including 57
patients who died within 6 weeks postoperatively (early
mortality \ 6 weeks = 1.9 %). Twelve patients were lost
to follow-up and were also excluded from our analysis.
Based on the TPG the patients were split into three
groups: patients with a low TPG (\10 mmHg), n = 876;
patients with a medium TPG (10–19 mmHg), n = 1,184;
and patients with a high TPG (C20 mmHg), n = 204.
Patient characteristics are summarized in Table 1.
Surgical technique
All patients underwent surgery using a standard technique.
After a median sternotomy, the ascending aorta and right
atrium were cannulated and normothermic extracorporeal
circulation with non-pulsatile flow was instituted. Myo-
cardial protection was obtained using cold crystalloid car-
dioplegia (St. Thomas solution) or warm blood
cardioplegia according to the surgeon’s preference. Car-
dioplegia was administered in an antegrade fashion through
the aortic root and/or selectively in both coronary ostia to
induce and maintain cardiac arrest. Retrograde adminis-
tration of cardioplegia was not used. Concomitant myo-
cardial revascularization was performed in 958 patients.
Implantation of the biggest valve possible and using
prosthetic valves with optimal hemodynamic profiles in
patients with small annular size were strategies used to
minimize the incidence of PPM. No aortic annulus
enlargement techniques were used. An overview of
implanted prosthetic valve types is shown in Table 2.
Prosthesis–patient mismatch (PPM)
PPM was expressed by the EOAI. The EOAI was calcu-
lated by dividing the corresponding EOA of each valve
type and size (registered in vitro values published by each
manufacturer) by each patient’s BSA [1, 6]. PPM was
defined as EOAI B0.85 cm2/m2 and severe PPM as EOAI
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\0.65 cm2/m2 [1, 3, 4]. There was no significant differ-
ence in the prevalence of PPM between patients who died
within 6 weeks postoperatively (n = 57) and the final
study population (n = 2,264) (10.5 vs 10.6 %, respec-
tively; p = 0.994). There were no cases of severe PPM
within the early deaths.
Echocardiographic follow-up
All patients underwent postoperative transthoracic echo-
cardiography (TTE) evaluation of the mean aortic valve
pressure gradient 6 weeks after surgery. Mean pressure
gradients were calculated using the modified Bernoulli
equation with correction for subvalvular velocities. Two
cardiologists, who have a long experience in echocardi-
ography, supervised these measurements.
Follow-up and late mortality
Follow-up data concerning mortality were gathered using
the databases of the civil registry. The remaining data that
could not be retrieved from these databases were obtained
by contacting patients’ general practitioners. Twelve
patients were lost to follow-up; mean follow-up was
Table 1 Characteristics for each pressure gradient group (n = 2,264)
Variable Low gradient Moderate gradient High gradient p
(\10 mmHg) n = 876 (10–19 mmHg) n = 1,184 (C20 mmHg) n = 204
Age (years) 70 ± 10 67 ± 11 65 ± 12 \0.001
Sex
Female 328 (37.4) 448 (37.8) 56 (27.5) 0.015
Endocarditis 27 (3.1) 54 (4.6) 14 (6.9) 0.035
Preoperative LV function
Severely impaired (EF \ 30 %) 39 (4.5) 27 (2.3) 4 (2.0) 0.012
Hypertension 406 (46.3) 549 (46.4) 78 (38.2) 0.085
Diabetes mellitus 151 (17.2) 203 (17.1) 33 (16.2) 0.934
Body weight (kg) 77 ± 13 79 ± 14 81 ± 16 \0.001
Height (cm) 170 ± 9 170 ± 9 171 ± 9 0.172
Body surface area, BSA (m2) 1.88 ± 0.19 1.91 ± 0.19 1.92 ± 0.21 0.002
Body mass index, BMI (kg/m2) 26.8 ± 4.0 27.4 ± 4.2 27.5 ± 4.7 0.006
Peripheral vascular disease (PVD) 108 (12.3) 111 (9.4) 20 (9.8) 0.091
Renal dysfunction 46 (5.3) 65 (5.5) 11 (5.4) 0.972
Chronic obstructive pulmonary disease (COPD) 144 (16.4) 194 (16.4) 41 (20.1) 0.404
Cerebrovascular accident (CVA) 36 (4.1) 64 (5.4) 12 (5.9) 0.305
Previous cardiac surgery 64 (7.3) 85 (7.2) 31 (15.2) \0.001
Additive EuroSCORE 6.2 ± 2.5 5.9 ± 2.5 5.8 ± 2.5 0.052
Logistic EuroSCORE 7.93 ± 8.33 7.06 ± 7.06 7.18 ± 7.69 0.075
Prosthetic valve diameter, mm
Median 23 23 23
Prosthetic valve type
Mechanical 367 (41.9) 580 (52.3) 120 (58.8) \0.001
Concomitant coronary artery bypass grafting 424 (48.4) 464 (39.2) 66 (32.4) \0.001
Cardiopulmonary bypass time (min) 95 ± 37 91 ± 36 93 ± 32 0.024
Aortic cross-clamp time (min) 70 ± 26 68 ± 25 68 ± 22 0.147
Effective orifice area (EOA) (cm2) 2.16 ± 0.48 2.06 ± 0.42 1.94 ± 0.40 \0.001
Indexed effective orifice area (EOAI) (cm2/m2) 1.15 ± 0.24 1.08 ± 0.21 1.01 ± 0.21 \0.001
PPM (EOAI B0.85 cm2/m2) 43 (4.9) 145 (12.2) 51 (25.0) \0.001
Severe PPM (EOAI \0.65 cm2/m2) 2 (0.2) 2 (0.2) 3 (1.5) 0.007
Mean transprosthetic gradient, TPG (mmHg) 6 ± 3 13 ± 3 28 ± 11 \0.001
Mean follow-up (years) 5.1 ± 3.5 5.7 ± 3.5 5.5 ± 3.5 \0.001
Data are presented as mean ± standard deviation or number (%)
EF ejection fraction, LV left ventricular, PPM prosthesis–patient mismatch
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5.5 ± 3.5 years (range 0.1–14.7 years). Patients lost to
follow-up were excluded from our analysis. Late mortality
was defined as all-cause death occurring later than 6 weeks
after surgery.
Statistics
Continuous variables were expressed as mean ± SD. Cat-
egorical variables were expressed as percentages. Mean
values were compared by using one-way ANOVA or its
non-parametric alternative, the Kruskal–Wallis test, for
continuous variables and Pearson’s Chi-squared test for
categorical variables.
Cumulative probability values of survival were esti-
mated with Kaplan–Meier method and compared between
groups using log-rank test.
Cox proportional-hazard regression analysis was used
to determine univariate predictors and multivariate inde-
pendent predictors of late mortality. Hazard ratios (HR)
were reported with 95 % confidence intervals (CI).
Variables considered as potential predictors for multivar-
iable modeling were selected by univariate analyses
(p \ 0.05) and were subsequently selected by stepwise
forward selection, with entry and retention in the model
set at a significance level of 0.05. Goodness of fit of the
final model was assessed with the Chi-squared goodness-
of-fit test.
All calculations were performed using a commercially
available statistical package (SPSS 20.0; SPSS Inc., Chi-
cago, IL). Statistically significant differences were estab-
lished at p \ 0.050.
Results
Characteristics of the patient population
Patient characteristics are shown in Table 1. There were
significantly more patients with endocarditis, a higher body
weight, a higher BSA and BMI, a mechanical valve, male
gender, previous cardiac surgery and a higher rate of PPM
and severe PPM in the high gradient group. Patients in the
high gradient group had a significantly lower age, EOA and
EOAI. The low-gradient group had significantly more
patients with a severely impaired LV function and more
patients undergoing concomitant CABG. There were no
significant differences between the three groups in other
comorbidities, such as hypertension, diabetes, PVD, renal
dysfunction, COPD and history of CVA. There was no
significant difference in additive or logistic EuroSCORES
between the groups.
Long-term survival
Mean follow-up was 5.5 years (range 0.1–14.7 years).
Total follow-up was 12,405 patient-years. Long-term sur-
vival for the entire group at 1, 3, 5, and 10 years was 97,
93, 87 and 67 %, respectively.
Survival at 1, 3, 5, and 10 years was 97, 92, 85, 66 %,
respectively, for the low-gradient group, 98, 94, 99 and
68 %, respectively, for the medium gradient group and 95,
92, 87, 66 %, respectively, for the high gradient group.
Figure 1 displays the long-term survival after transtho-
racic echocardiographic (TTE) evaluation of the TPG,
6 weeks after surgery stratified per gradient group. Dif-
ference in survival between the groups was not significant
(p = 0.258).
Predictors of late mortality
The results of Cox regression analysis for late mortality are
shown in Table 3.
Univariate analysis revealed the following predictors of
late mortality: age, severely impaired LV function [25],
hypertension, diabetes, PVD, renal dysfunction [25],
COPD, history of CVA, the use of a mechanical prosthesis,
concomitant CABG, CPB time and aortic cross-clamp
time. PPM, severe PPM and TPG as a continuous variable
or as categorical variable (gradient group) were not sig-
nificant predictors of late mortality at univariate analysis.
Multivariate analysis revealed the following indepen-
dent predictors of late mortality: age, diabetes, PVD, renal
dysfunction [26], COPD, history of CVA and CPB time.
The use of a mechanical prosthesis, concomitant CABG,
aortic cross-clamp time, and TPG were not independent
predictors of late mortality at multivariate analysis.
Table 2 Prosthetic valve distribution (n = 2,264)
Variable Value




St. Jude Medical Standard 577 (25.5)
ATS 377 (16.7)
St. Jude Medical Regent 77 (3.4)
St. Jude Medical HP 36 (1.6)
Biological (stented) 1,197 (52.9)
Carpentier–Edwards Magna 142 (6.3)
Carpentier-Edwards Perimount 412 (18.2)
Sorin Mitroflow 291 (12.9)
Medtronic Mosaic 98 (4.3)
St. Jude Trifecta 87 (3.8)
St. Jude Medical Epic 167 (7.4)
Data are number of patients (%)
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Goodness of fit of the final model was assessed with the
Chi-squared goodness-of-fit test: p \ 0.001.
Comment
This study shows that a higher TPG measured at 6 weeks
after surgery is not identified as an independent predictor of
late mortality after AVR or AVR with CABG. This finding
is reassuring when confronted with a postoperative pres-
sure gradient at 6 weeks TTE follow-up.
However, we do not have follow-up data concerning the
evolution of the TPG after 6 weeks. In most cases, the
gradient measurement at 6 weeks will take place in a stable
situation. The TPG measured in this condition will most
likely be representative for the future since prosthetic-
related factors, such as EOA, hemodynamic profile and
surgeon-related factors such as suturing technique and
sizing which may play a role in creating a TPG are already
defined at that point. The etiology of TPG is complex and
multifactorial and patient-related factors such as pannus
[27] and thrombus formation may evolve over time. Pannus
formation is a bio-reaction to the prosthesis [28–30], usu-
ally originating from the ventricular site and its structure
Fig. 1 Long-term survival after transthoracic echocardiographic
(TTE) evaluation of the mean transprosthetic pressure gradient
(TPG) 6 weeks after surgery stratified per gradient group. Difference
in survival between the groups was not significant (p = 0.258)
Table 3 Univariate and
multivariate Cox analysis of late
([6 weeks) mortality
CI confidence interval, EF
ejection fraction, HR hazard
ratio, LV left ventricular
a Entered as a continuous
variable
b Compared to low-gradient
group
c Compared to biological
valves
Variable Univariate analysis Multivariate analysis
p HR (95 % CI) p HR (95 % CI)
Age (years)a \0.001 1.07 (1.06–1.08) \0.001 1.06 (1.05–1.08)
Sex (female) 0.804 1.03 (0.84–1.25)
Severely impaired LV function (EF \ 30 %) 0.040 1.57 (1.02–2.41) 0.062 1.51 (0.98–2.34)
Hypertension 0.003 1.33 (1.10–1.61) 0.449 1.08 (0.89–1.31)
Diabetes mellitus \0.001 1.81 (1.44–2.29) 0.003 1.44 (1.13–1.83)
Endocarditis 0.115 0.62 (0.34–1.12)
Gradient groupb
10–19 mmHg 0.107 0.85 (0.69–1.04) 0.781 0.97 (0.79–1.19)
C20 mmHg 0.815 0.96 (0.69–1.34) 0.496 1.13 (0.80–1.59)
Gradienta 0.156 0.99 (0.98–1.00)
Body mass index, BMI (kg/m2) 0.535 1.01 (0.98–1.03)
Peripheral vascular disease (PVD) \0.001 2.37 (1.84–3.06) \0.001 1.81 (1.40–2.35)
Renal dysfunction \0.001 2.21 (1.53–3.18) 0.007 1.66 (1.15–2.41)
Chronic obstructive pulmonary disease (COPD) \0.001 1.70 (1.37–2.12) \0.001 1.70 (1.37–2.13)
Cerebrovascular accident (CVA) \0.001 2.09 (1.50–2.92) 0.001 1.78 (1.27–2.49)
Mechanical prosthetic valvec \0.001 0.45 (0.37–0.55) 0.394 0.90 (0.70–1.15)
Concomitant coronary artery bypass grafting
(CABG)
\0.001 1.56 (1.29–1.88) 0.920 0.99 (0.79–1.24)
Cardiopulmonary bypass (CPB) time (min)a \0.001 1.01 (1.00–1.01) 0.011 1.00 (1.00–1.01)
Aortic cross-clamp time (min)a \0.001 1.01 (1.00–1.01) 0.495 1.00 (0.99–1.00)
Prosthesis–patient mismatch (PPM) (EOAI
B0.85 cm2/m2)
0.175 1.20 (0.92–1.56)
Severe PPM (EOAI \0.65 cm2/m2) 0.423 1.77 (0.44–7.09)
Previous cardiac surgery 0.151 1.29 (0.91–1.82)
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consists mainly of myofibroblasts and an extracellular
matrix such as collagen fiber [31] and thrombus can be a
primary cause of pannus formation [32]. On the other hand,
a TPG can induce shear stress in the peri-annular tissue,
which may also contribute to pannus formation [31].
Although pannus ingrowth can occur in the late postoper-
ative period (mean interval from previous operation
9.6 ± 2.0 years reported by Kuniyoshi et al. [33]), valve-
related complications due to pannus formation are rare
(incidence 0.2–4.5 % per patient year [34]) and scarcely an
issue with contemporary mechanical prostheses.
Late mortality is not affected by TPG probably
because the gradient measured at 6 weeks after surgery is
not likely to increase significantly [35]. Zimmerli et al.
[36] found that slight long-term increases in mean pres-
sure gradients are normal findings and do not warrant a
change in management strategy if unaccompanied by
deterioration of symptoms or clinical signs. Postoperative
TPG has to be interpreted differently than the preopera-
tive gradient measured in patients with aortic valve ste-
nosis, which is a progressive disease with increasing
gradients over time [37]. In most cases a high TPG will
still be a significant reduction in hemodynamic burden for
the left ventricle compared to the even higher preopera-
tive aortic valve gradient. This improved and stable sit-
uation for the conditioned left ventricle could be another
explanation for the lack of influence of TPG on late
mortality.
Although there was no significant difference in additive
and logistic EuroSCORES [38, 39] and both study popu-
lations were homogeneous for most risk factors, some
baseline patient characteristics were significantly different
between the two groups. Patients in the high gradient group
not only had a significantly higher BSA, but also a lower
EOA resulting in a higher prevalence of PPM and severe
PPM in this group. Nevertheless, PPM and severe PPM
were not significant predictors of late mortality and there-
fore unlikely to have a negative effect on survival in the
high gradient group. The fact that PPM does not affect
long-term survival is consistent with other studies [7, 19,
24, 40–44].
Most operative characteristics, such as the use of
mechanical valve prostheses, concomitant CABG, CPB
time, aortic cross-clamp time were significantly different
between the groups. Only CPB time was an independent
predictor of late mortality whereas aortic cross-clamp time
was not. Aortic cross-clamp time is a reflection of the
duration of the technical repair, whereas CPB time is a
reflexion of the duration of the technical repair time and the
time the patient needs to wean from CPB, hence a reflexion
of the general condition of the heart.
An important limitation is the retrospective design of
this study. Therefore, some baseline patient characteristics
were significantly different between the gradient groups.
However, there was no significant difference in most
comorbidities and EuroSCORES between the groups.
Secondly, we focussed on the patients undergoing TTE
follow-up at 6 weeks after surgery and the effect of a high
TPG on late mortality, thus excluding patients that died
before having their TTE follow-up at 6 weeks. The low
prevalence of severe PPM (n = 7, 0.3 %), possibly caused
by the above-mentioned surgical strategies to avoid PPM,
limits the statistical analysis of this group. On the other
hand, it is important to note that severe PPM is extremely
rare when using straightforward surgical strategies to avoid
PPM. In addition, the primary end-point was all-cause
mortality. We were not able to retrieve the cause of death
that might be equally important and we did not have any
information about quality of life after AVR in relation to
the TPG. Finally, the relatively short mean follow-up of
5.5 years also limits conclusions about the long-term effect
of TPG on survival.
Conclusions
In conclusion, our findings indicate that TPG measured at
6 weeks after AVR or AVR with CABG is not an inde-
pendent predictor of all-cause late mortality and there is no
significant difference in long-term survival between
patients with a low, medium or high TPG.
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